Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes

NCT00411905 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndromes

Interventions

DRUG: Bortezomib

Sponsor

Groupe Francophone des Myelodysplasies

Collaborators

[object Object]